In life sciences, and particularly pharmaceuticals, the ERP landscape is incredibly complex. This is one of the most highly regulated industries in the world, where requirements shift across both the production and product lifecycle and every process is overseen in detail by regulatory authorities. From discovery and development through to manufacturing, packaging, and labelling, patient safety is the top priority. Medicines must not only be effective but must also be produced under strict Good Manufacturing Practice (GMP) guidelines. Here, ERP is not just a tool for efficiency; when paired with compliant, well-designed processes, it underpins the delivery of safe, consistent, and effective products.
Manufacturing a dosage form involves three distinct phases:
API production may take place in-house or it can be outsourced to a Contract Manufacturing Organisation (CMO), which may also handle the secondary manufacturing. Packaging is typically done at the same premises.
Implementing an ERP system in life sciences therefore presents distinct challenges compared to other industries. The sections that follow explore these in detail, highlighting how ERP can address these industry-specific demands across the full product journey.
Scalability: As a product moves from clinical trials to commercialisation, the size of each batch increases dramatically. At this stage, even the tiniest error in calculating the quantity of active ingredients or excipients can render an entire batch unusable.
To prepare for this scale-up, an intermediate batch is first manufactured at pilot scale using a process that simulates full-scale production. This step helps develop the master formula. However, success at small or pilot scale does not always translate into success at commercial scale. Critical process parameters must be carefully controlled through optimisation, with close attention to measuring both the physical and chemical stability of intermediates. Factors such as changes in equipment, process speed, temperature, or packaging type can all alter how ingredients behave during manufacturing.
An ERP system that supports both small-scale and large-scale production, without requiring replacement as operations expand, is therefore essential in pharma.
Active ingredient management: In drug manufacturing, the active ingredient is produced first and stored until it is needed for the final product. Any time gap between its production and the manufacture of the finished drug must be deducted from the product’s overall shelf life.
Because active ingredients vary in potency, calculating the correct quantity for each formulation is both critical and drug-specific. Manufacturers must accurately measure and manage the potency of all ingredients in every batch to ensure consistent formulations. An effective ERP system should fully support these requirements, helping maintain quality and compliance throughout the manufacturing process.
Excipient management: Excipients are classified as inactive substances that serve as carriers for active ingredients, but their role extends far beyond that. They influence solubility, stability, the biopharmaceutical profile, product appearance, patient acceptability, and ease of manufacturing. Because of this, excipient quality is critical to ensuring that the final product meets all regulatory and quality standards.
An effective ERP system should be able to flag any quality issues identified during raw material testing and, where possible, recommend alternative suppliers to safeguard continuity of supply and maintain product integrity.
Batch management: In manufacturing, a batch refers to a set of identical products that share defined production characteristics. Each batch is assigned a unique alphanumeric identifier—often called a batch number, lot number, or batch code—used to trace details such as production time and date, identification code, dosage strength, and even the specific APIs and their attributes. This information can also include expiry dates, manufacturing line and time, and, where applicable, retest dates to extend shelf life if quality requirements are met.
Batch attributes are central to serialisation, which plays a critical role in securing market authorisation and meeting compliance and safety requirements. Importantly, two batches of the same material may yield different outcomes—for example, one may be released for use while another is placed on hold, reprocessed, or rejected—depending on quality results and company procedures.
Robust batch management is also essential for recalls. With precise monitoring, companies can limit recalls to only the affected products rather than withdrawing entire ranges, avoiding unnecessary disruption and cost while protecting patient safety. ERP systems can make batch management more efficient, transparent, compliant, and cost-effective, while reducing the risks associated with quality failures or recalls.
Serialisation: Pharma serialisation is the process of assigning a unique code to the packaging of each drug and printing it on the pack. The structure and format of the code are defined by the regulations of each country. Packaging may be primary, secondary, or tertiary, and serialisation is only considered complete once the unique code is printed on it. Being able to identify products through serialisation is vital for the following processes:
A typical drug distribution system involves manufacturers, wholesale distributors, and pharmacies, with products passing through many hands before reaching patients. Secure track-and-trace capabilities, enabled by product serialisation, are essential to safeguard this chain. They help the industry as a whole tackle challenges such as counterfeit medicines, regulatory compliance, and patient safety. At the same time, they give individual pharmaceutical companies a clear advantage by improving supply chain visibility, reducing the cost and disruption of recalls, and strengthening trust with partners and regulators.
An ERP system (ex. SAP Advanced Track and Trace for Pharmaceuticals) provides this end-to-end visibility by making sure all the products are traced back to origin, and forward to their destination.
Recalls are triggered when products are defective or potentially unsafe, and may involve current batch levels, stock on open orders, or goods already delivered to customers. Incidents leading to recall can include quality, safety, or efficacy issues.
There are several reasons why stock may be quarantined. For example, it may be temporarily held to allow QA specialists to verify compliance before distribution; it may also occur in short-stock situations to avoid misdirected shipments. Some warehouses also quarantine stock during put-away, ensuring that order lines and inbound receipts aren’t disrupted by replenishment and that the supply chain continues without interruption. Efficient quarantine processes ensure supply chains remain compliant, on time, and disruption-free.
Quality problems can also lead to broader supply chain risks, such as stock-outs. Common triggers include:
When a recall is necessary, the ERP system must be able to trace the location of affected products or components (batch tracking) quickly and accurately. This is done by assigning a serial number and a lot number to the product as well as its components, which delivers full end-to-end traceability for safety, compliance, logistics and regulatory requirements.
The complexity of the global pharmaceutical supply chain makes it difficult to prevent counterfeit medicines from entering the market. Manufactured medicines are often stored, distributed, and consumed in different countries. Serialisation addresses this risk not only by uniquely identifying finished products, but also by tracing raw materials back to their vendor batch numbers. This provides visibility from manufacturing through to the point the product reaches the customer.
An ERP system plays a key role in making serialisation automatic, compliant, and fully traceable. Therefore, it plays a vital role in eliminating counterfeit medicines, ensuring regulatory compliance, protecting consumers, and safeguarding brand reputation.
E-signatures: As life sciences companies grow, many are moving toward paperless environments to improve efficiency, cut costs, meet regulatory standards more effectively and maintain complete visibility of their processes. This shift brings electronic records under the scope of 21 CFR Part 11 regulations, which require the use of secure electronic signatures. Embedding e-signature capability within an ERP system has therefore become a major benefit for pharmaceutical organisations.
E-signatures are mostly used in the quality function. For example, inventory placed on hold while awaiting batch quality testing cannot be released for shipping until a Qualified Person (QP) confirms the result. That decision—pass, fail, or re-test—is increasingly verified electronically, with layered authorisation controls, to prevent fraud and ensure accountability. E-signatures also provide validation and visibility by confirming which authorised personnel approved the movement or release of inventory after quality control.
During production, line managers must approve batch documentation before manufacturing begins, including raw materials, recipes, and version controls. Any missing data can cause production delays. Today, these approvals are mostly performed digitally using mobile devices. Document management systems like Veeva Quality Doc are integrated with ERP systems to enforce secure, compliant, and auditable e-signatures, ensuring regulatory compliance while improving speed and efficiency.
Stock release before shipping: Specific to life sciences, products undergo testing at multiple points during and after manufacturing to ensure they meet the required standards. Raw materials are first sampled and tested before use, and intermediates are also checked at different stages of production to confirm ongoing quality. Once manufacturing is complete, the finished product is tested again prior to packaging, with microbiological and chemical testing performed as required by each product.
Most products are held in storage before dispatch to allow time for these tests to be completed and storage times can vary considerably between different products. Once they are ready for dispatch, stability tests are carried out to ensure the product is stable and safe for use. Retained samples will also be held for several years. In this instance, an effective ERP system will manage complex testing, storage, and release requirements before products reach patients.
Controlled drug management: Different drugs can have vastly different storage and handling requirements in terms of temperature, humidity, and lighting depending on their classification. In addition to these physical safeguards, companies must comply with local regulations that govern how controlled substances are stored, tracked, and managed. The controls may need to be demonstrated not only via systems but also paper documentation. ERP systems act as a backbone tool for dealing with all the challenges mentioned above.
Environmental monitoring: Environmental monitoring is critical in both pharmaceutical and cosmetics manufacturing to prevent the release of contaminated products and ensure consistent product quality. It is especially important in the production of sterile (aseptic) medicines such as injections, where even the smallest deviation in environmental conditions can compromise patient safety. By connecting ERP systems directly with environmental monitoring tools, companies can capture and analyse data in real time, enabling proactive responses to risks.
Commercialisation: Once a new drug or device is approved, pharmaceutical companies face the challenge of scaling rapidly and managing a wide range of interconnected processes. An ERP system must be able to integrate seamlessly with manufacturers and 3PL (third-party logistics) providers, while also supporting sales and marketing, product planning, and quality management. Just as importantly, it needs the flexibility to adapt quickly to evolving business processes and shifting regulatory requirements, while offering best-practice guidance. By providing visibility across operations, ERP enables life sciences firms to identify and respond quickly to any current or potential product quality risks, failures or customer complaints.
Cost management: An obvious, key concern for a life sciences company is the management of costs. An ERP system should provide real-time monitoring of vendor pricing, material costs, and other spending variables, giving companies full visibility into day-to-day expenses. It should also automate cost oversight by flagging exceptions and offering tools to model alternative sourcing options. Crucially, it should track procurement costs in detail, showing how much is being paid to suppliers and where those expenses are going. By combining oversight with automation, ERP enables pharmaceutical companies to manage supplier spend more efficiently while maintaining quality and reliability.
Cold storage management: Many pharmaceutical companies and CDMOs face issues with maintaining manufactured drug products at rigorous cold storage standards, which are critical for the efficacy and shelf-life of temperature-sensitive drugs. Adherence to these requirements can be very challenging, especially when the products need to be transported from/to various points of use.
An ERP system that can handle secure cold chain logistics at every step is essential for the efficient storage and distribution of medicines to the patients.
HCP Reporting: Life sciences companies are subject to strict regulations that limit and monitor their aggregate spending on healthcare professionals (HCPs). Non-compliance can result in heavy fines and, more damagingly, a loss of trust with regulators and the public. Tracking this spend is complex because it cuts across many systems and functions, covering both direct and indirect payments. These may include consulting fees, royalties, travel, meals, gifts, and other sales and marketing expenditures.
Effective HCP reporting requires strong change management and organisational alignment. Companies must establish clear policies, define roles and responsibilities, and implement consistent administrative procedures. Here, ERP plays a critical role by consolidating data from different business functions into a single system of record. This integration gives companies visibility over total HCP spend, automates reporting, and flags potential compliance risks before they escalate. When backed by strong executive commitment, an ERP-enabled reporting process helps ensure regulatory compliance while protecting the company’s reputation.
Supplier / Customer / Partner collaboration: Life sciences companies are part of a broad ecosystem that stretches from early drug discovery to delivery to the patient. Ensuring continuity of supply is not only an ethical responsibility but, in some countries, a legal requirement. To achieve this, companies need efficient collaboration across the entire supply chain. Tools such as system interfaces, electronic data interchange (EDI), and vendor-managed inventory can make these interactions seamless.
Collaboration is equally important in research and development, where partnerships with other pharmaceutical companies, research institutes, and universities are now common practice. An ERP system strengthens this wider network by integrating information flows, improving visibility across partners, and supporting real-time collaboration.
High governance by regulatory authorities: Pharmaceutical companies operate in one of the most highly regulated sectors, where patient and customer safety is paramount. Regulatory authorities set strict standards and validate critical areas such as manufacturing, plant maintenance, quality control, audit trails, and GxP compliance.
An ERP system tailored for life sciences provides the structure needed to manage these requirements effectively. By documenting business processes and capturing time-stamped transactional data in an integrated system, ERP creates a clear, auditable record of activity. This level of traceability not only proves compliance but also strengthens confidence among regulators, partners, and patients that safety and quality are consistently maintained.
Summary of Abbreviations:
GMP – Good Manufacturing Practice
GxP – Good Practices
CDMO – Contract Development and Manufacturing Organisation.
Expanding market presence and maximising synergies
Through planning and due diligence to
execution and stabilisation
Understanding the levers for
successful integration
Expertly navigate the challenges and
risks
Unpick the opportunities to drive the
bottom line
Disentangling a well-established site from a complex corporate infrastructure-with stringent timelines, local compliance challenges, and a rigid transitional services agreement (TSA) in place.
Redefining strategy to make process improvements and cost savings
Expertly navigate the challenges and
risks.
Combining processes, systems and
people to deliver maximum results
Working with what you've got to make
things even better
Making your data work for you to deliver
real insight
How we streamlined and future-proofed, a soon-to-be obsolete labelling solution and a rapid client expansion across multiple new sites.
Reinventing finance to optimise processes, systems and strategies
Enhancing decision making and strategic
alignment to drive performance
Using the latest technology to drive efficiencies, innovation and operational excellence
Meeting local requirements while
delivering smooth cross-border
operations
Simplifying supply chain finance
Improving compliance accuracy and
automation using tax technology
